Orexigen's Empatic Phase 2b results demonstrate weight loss
Links shared publicly online about this topic.
- 1,708total visits
Orexigen's Empatic Phase 2b results demonstrate weight loss
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
View full resource at news-medical.net
Tags: Obesity, Antidepressant, Weight Loss, Smoking Cessation Medication, Wellbutrin, Zyban, News
Most Recently Shared on October 1, 2009 at 7:05 pm By:
Obesity News: Orexigen's Empatic Phase 2b results demonstrate weight loss: Orexigen Therapeutics, .. http://twurl.nl/fj6ep0
Phase 2b study of Empatic for weight loss - MPR
empr.com — “Orexigen Therapeutics announced positive results from its Phase 2b trial for Empatic (bupropion SR/zonisamide SR), its investigational combination drug for the treatment of obesity.” View full resource at empr.com
Most Recently Shared on September 30, 2009 at 4:42 pm By:
MPR News: Phase 2b study of Empatic for weight loss: Orexigen Therapeutics announced positive results .. http://tinyurl.com/ydbvnju
Advertisement
